Nonattenuated Polymyxin B Used for the Treatment of Extreme-Drug Resistant Acinetobacter baumannii-Related Infections in Patients with Preexisting End Stage Renal Failure

Recent pharmacokinetic studies have suggested that nonrenal clearance predominates the elimination of polymyxin B. We present 2 patients with preexisting end stage renal failure, who were given nonattenuated doses of polymyxin B for the treatment of extreme-drug resistant organism. No evidence of ad...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Yvonne Peijun, Chua, Nathalie Grace Sy, Chlebicki, Maciej Piotr, Lee, Winnie Hui Ling, Kwa, Andrea Lay Hoon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2014
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4065743/
https://www.ncbi.nlm.nih.gov/pubmed/24995135
http://dx.doi.org/10.1155/2014/573279
_version_ 1782322136266833920
author Zhou, Yvonne Peijun
Chua, Nathalie Grace Sy
Chlebicki, Maciej Piotr
Lee, Winnie Hui Ling
Kwa, Andrea Lay Hoon
author_facet Zhou, Yvonne Peijun
Chua, Nathalie Grace Sy
Chlebicki, Maciej Piotr
Lee, Winnie Hui Ling
Kwa, Andrea Lay Hoon
author_sort Zhou, Yvonne Peijun
collection PubMed
description Recent pharmacokinetic studies have suggested that nonrenal clearance predominates the elimination of polymyxin B. We present 2 patients with preexisting end stage renal failure, who were given nonattenuated doses of polymyxin B for the treatment of extreme-drug resistant organism. No evidence of adverse events occurred and microbiological clearance was documented.
format Online
Article
Text
id pubmed-4065743
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-40657432014-07-03 Nonattenuated Polymyxin B Used for the Treatment of Extreme-Drug Resistant Acinetobacter baumannii-Related Infections in Patients with Preexisting End Stage Renal Failure Zhou, Yvonne Peijun Chua, Nathalie Grace Sy Chlebicki, Maciej Piotr Lee, Winnie Hui Ling Kwa, Andrea Lay Hoon Case Rep Infect Dis Case Report Recent pharmacokinetic studies have suggested that nonrenal clearance predominates the elimination of polymyxin B. We present 2 patients with preexisting end stage renal failure, who were given nonattenuated doses of polymyxin B for the treatment of extreme-drug resistant organism. No evidence of adverse events occurred and microbiological clearance was documented. Hindawi Publishing Corporation 2014 2014-06-03 /pmc/articles/PMC4065743/ /pubmed/24995135 http://dx.doi.org/10.1155/2014/573279 Text en Copyright © 2014 Yvonne Peijun Zhou et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Zhou, Yvonne Peijun
Chua, Nathalie Grace Sy
Chlebicki, Maciej Piotr
Lee, Winnie Hui Ling
Kwa, Andrea Lay Hoon
Nonattenuated Polymyxin B Used for the Treatment of Extreme-Drug Resistant Acinetobacter baumannii-Related Infections in Patients with Preexisting End Stage Renal Failure
title Nonattenuated Polymyxin B Used for the Treatment of Extreme-Drug Resistant Acinetobacter baumannii-Related Infections in Patients with Preexisting End Stage Renal Failure
title_full Nonattenuated Polymyxin B Used for the Treatment of Extreme-Drug Resistant Acinetobacter baumannii-Related Infections in Patients with Preexisting End Stage Renal Failure
title_fullStr Nonattenuated Polymyxin B Used for the Treatment of Extreme-Drug Resistant Acinetobacter baumannii-Related Infections in Patients with Preexisting End Stage Renal Failure
title_full_unstemmed Nonattenuated Polymyxin B Used for the Treatment of Extreme-Drug Resistant Acinetobacter baumannii-Related Infections in Patients with Preexisting End Stage Renal Failure
title_short Nonattenuated Polymyxin B Used for the Treatment of Extreme-Drug Resistant Acinetobacter baumannii-Related Infections in Patients with Preexisting End Stage Renal Failure
title_sort nonattenuated polymyxin b used for the treatment of extreme-drug resistant acinetobacter baumannii-related infections in patients with preexisting end stage renal failure
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4065743/
https://www.ncbi.nlm.nih.gov/pubmed/24995135
http://dx.doi.org/10.1155/2014/573279
work_keys_str_mv AT zhouyvonnepeijun nonattenuatedpolymyxinbusedforthetreatmentofextremedrugresistantacinetobacterbaumanniirelatedinfectionsinpatientswithpreexistingendstagerenalfailure
AT chuanathaliegracesy nonattenuatedpolymyxinbusedforthetreatmentofextremedrugresistantacinetobacterbaumanniirelatedinfectionsinpatientswithpreexistingendstagerenalfailure
AT chlebickimaciejpiotr nonattenuatedpolymyxinbusedforthetreatmentofextremedrugresistantacinetobacterbaumanniirelatedinfectionsinpatientswithpreexistingendstagerenalfailure
AT leewinniehuiling nonattenuatedpolymyxinbusedforthetreatmentofextremedrugresistantacinetobacterbaumanniirelatedinfectionsinpatientswithpreexistingendstagerenalfailure
AT kwaandrealayhoon nonattenuatedpolymyxinbusedforthetreatmentofextremedrugresistantacinetobacterbaumanniirelatedinfectionsinpatientswithpreexistingendstagerenalfailure

Ejemplares similares